Spruce Biosciences (SPRB) Competitors $150.86 -6.96 (-4.41%) As of 01:59 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock SPRB vs. DMAC, UPXI, REPL, LRMR, ALT, CADL, ACIU, CTNM, GALT, and TNYAShould you be buying Spruce Biosciences stock or one of its competitors? The main competitors of Spruce Biosciences include DiaMedica Therapeutics (DMAC), Upexi (UPXI), Replimune Group (REPL), Larimar Therapeutics (LRMR), Altimmune (ALT), Candel Therapeutics (CADL), AC Immune (ACIU), Contineum Therapeutics (CTNM), Galectin Therapeutics (GALT), and Tenaya Therapeutics (TNYA). These companies are all part of the "pharmaceutical products" industry. Spruce Biosciences vs. Its Competitors DiaMedica Therapeutics Upexi Replimune Group Larimar Therapeutics Altimmune Candel Therapeutics AC Immune Contineum Therapeutics Galectin Therapeutics Tenaya Therapeutics Spruce Biosciences (NASDAQ:SPRB) and DiaMedica Therapeutics (NASDAQ:DMAC) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, dividends, media sentiment, profitability, institutional ownership, analyst recommendations and risk. Which has more risk & volatility, SPRB or DMAC? Spruce Biosciences has a beta of 2.47, indicating that its share price is 147% more volatile than the S&P 500. Comparatively, DiaMedica Therapeutics has a beta of 1.4, indicating that its share price is 40% more volatile than the S&P 500. Is SPRB or DMAC more profitable? DiaMedica Therapeutics' return on equity of -78.99% beat Spruce Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Spruce BiosciencesN/A -177.45% -118.06% DiaMedica Therapeutics N/A -78.99%-69.94% Do insiders and institutionals hold more shares of SPRB or DMAC? 91.7% of Spruce Biosciences shares are held by institutional investors. Comparatively, 10.1% of DiaMedica Therapeutics shares are held by institutional investors. 6.9% of Spruce Biosciences shares are held by insiders. Comparatively, 7.3% of DiaMedica Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Do analysts recommend SPRB or DMAC? Spruce Biosciences presently has a consensus target price of $131.25, suggesting a potential downside of 13.00%. DiaMedica Therapeutics has a consensus target price of $12.33, suggesting a potential upside of 83.94%. Given DiaMedica Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe DiaMedica Therapeutics is more favorable than Spruce Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Spruce Biosciences 1 Sell rating(s) 6 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.13DiaMedica Therapeutics 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50 Does the media refer more to SPRB or DMAC? In the previous week, Spruce Biosciences had 5 more articles in the media than DiaMedica Therapeutics. MarketBeat recorded 5 mentions for Spruce Biosciences and 0 mentions for DiaMedica Therapeutics. Spruce Biosciences' average media sentiment score of 0.69 beat DiaMedica Therapeutics' score of 0.00 indicating that Spruce Biosciences is being referred to more favorably in the media. Company Overall Sentiment Spruce Biosciences Positive DiaMedica Therapeutics Neutral Which has higher valuation and earnings, SPRB or DMAC? DiaMedica Therapeutics has lower revenue, but higher earnings than Spruce Biosciences. DiaMedica Therapeutics is trading at a lower price-to-earnings ratio than Spruce Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSpruce Biosciences$4.91M17.21-$53.04M-$86.21-1.75DiaMedica TherapeuticsN/AN/A-$24.44M-$0.69-9.72 SummaryDiaMedica Therapeutics beats Spruce Biosciences on 8 of the 15 factors compared between the two stocks. Get Spruce Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for SPRB and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SPRB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SPRB vs. The Competition Export to ExcelMetricSpruce BiosciencesPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$84.30M$1.05B$6.17B$10.68BDividend YieldN/A4.84%5.72%4.83%P/E Ratio-1.751.3129.4727.34Price / Sales17.2130.11587.77132.79Price / CashN/A17.6325.8230.35Price / Book2.888.1712.446.68Net Income-$53.04M-$7.36M$3.32B$276.46M7 Day Performance-5.12%-0.11%2.15%0.77%1 Month Performance1,696.23%28.58%8.41%3.73%1 Year Performance287.58%-12.71%61.67%36.59% Spruce Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SPRBSpruce Biosciences1.1336 of 5 stars$150.87-4.4%$131.25-13.0%+305.4%$84.30M$4.91M-1.7520Gap DownDMACDiaMedica Therapeutics1.0358 of 5 stars$7.02-0.6%$12.33+75.7%+51.6%$359.40MN/A-10.0820UPXIUpexi2.3972 of 5 stars$6.05-6.7%$15.50+156.3%+49.6%$351.81M$15.81M0.00130Gap UpREPLReplimune Group3.3469 of 5 stars$4.50-1.3%$6.50+44.5%-61.0%$348.54MN/A-1.38210Trending NewsAnalyst UpgradeGap UpLRMRLarimar Therapeutics3.1631 of 5 stars$4.13-2.9%$16.71+305.2%-45.9%$344.78MN/A-2.6730ALTAltimmune2.3594 of 5 stars$3.90-2.6%$17.40+346.4%-44.3%$340.24M$20K-3.2750Analyst ForecastCADLCandel Therapeutics2.6299 of 5 stars$6.13-5.2%$20.00+226.2%-12.0%$335.11M$120K-8.8560ACIUAC Immune1.5677 of 5 stars$3.27-5.9%$10.00+206.3%-7.3%$333.36M$31.02M-5.72140CTNMContineum Therapeutics1.91 of 5 stars$11.71-1.9%$22.20+89.7%-28.6%$332.13M$50M-5.3831GALTGalectin Therapeutics1.3307 of 5 stars$5.09-0.2%$6.00+17.9%+86.9%$323.18MN/A-7.889News CoverageGap UpTNYATenaya Therapeutics3.4045 of 5 stars$2.00+0.8%$6.25+213.3%-11.3%$321.40MN/A-2.05110Positive NewsGap Up Related Companies and Tools Related Companies DiaMedica Therapeutics Competitors Upexi Competitors Replimune Group Competitors Larimar Therapeutics Competitors Altimmune Competitors Candel Therapeutics Competitors AC Immune Competitors Contineum Therapeutics Competitors Galectin Therapeutics Competitors Tenaya Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SPRB) was last updated on 10/20/2025 by MarketBeat.com Staff From Our PartnersNEW LAW: Congress Approves Setup For Digital Dollar?Trump Ally Says Congress Approved the Setup for a Digital Dollar 2.0 But according to Rep. Marjorie Taylor ...Goldco Precious Metals | Sponsored$15 Fund: Turn Gold Boom into Real IncomeIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredTrump Issues Surprise Emergency OrderIs This Stock the 'Next Nvidia'? Billionaire Warren Buffett has been loading up on millions of shares of th...Altimetry | SponsoredNext opportunity for crypto millionsThe floodgates have opened. Bitcoin and Ethereum ETFs are seeing record-breaking inflows, the biggest since...Crypto 101 Media | SponsoredGold to $27,533?This week, U.S. gold reserves hit an unprecedented $1 TRILLION in value... And it's sparking urgent chatter...Stansberry Research | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Spruce Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Spruce Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
